
NAME: Kathleen Moore, MD

INSTITUTION: University of Oklahoma College of Medicine

OPEN SEAT: Society Board of Directors Designated Surgical Oncologist

A. EDUCATION, POSTDOCTORAL TRAINING, LICENSURE & CERTIFICATION

Education:

2007	M.S	University of Oklahoma Health Sciences Center School of Public Health (Epidemiology), Oklahoma City, OK
2000	M.D.	University of Washington School of Medicine, Seattle, WA
1992	B.A.	Rice University (Art and Art History), Houston, TX

Postdoctoral Training:

2004-2007	Fellow, Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
2000-2004	Resident, Department of Obstetrics and Gynecology, University Health Center of Pittsburgh Magee-Womens Hospital Residency Training Program, Pittsburgh, PA

B. APPOINTMENTS

Academic Appointments:

2021-	Professor, Department of Obstetrics and Gynecology
2019-	Virginia Kerley Cade Chair in Clinical Research
2015-2019	Jim and Christy Everest Endowed Chair in Cancer Research
2013-2020	Associate Professor, Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine
2010-2015	Mai Eager Anderson Chair in Cancer Clinical Trials
2007-2013	Assistant Professor, Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine

C. PROFESSIONAL SOCIETIES, COMMITTEE ASSIGNMENTS, EDITORIAL BOARDS

Administrative Leadership Positions:

Local

2019-	Medical Director for Infusion Services/Stephenson Cancer Center
2019-	GOG Foundation Board of Directors
2018-	Program Director, Protocol Support Unit (PSU), Stephenson Cancer Center
2018-	Associate Director Clinical Research/Stephenson Cancer Center
2016-	Medical Director, Clinical Trials Office/Stephenson Cancer Center
2016-	Associate Director Clinical Research/Stephenson Cancer Center
2015-	Director, TSET Phase I Drug Development Unit
2013-2021	Director, Gynecologic Oncology Fellowship
2010-2015	Associate Director, TSET Phase I Center
2007-2013	Associate Fellowship Director, Gynecologic Oncology

Regional

2020-2022 Director (2020-2021) and President (2021-2022), Western Association of Gynecologic Oncology (WAGO) Program

National

2019- Associate Director GOG Partners
2019- GOG Foundation Board of Directors
2019-2020 Society of Gynecologic Oncology Annual Meeting Program Co-Chair
2018- NRG Ovarian Cancer Committee Chair
2017-2021 Society of Gynecologic Oncology Board of Directors
2016- NRG/Gynecologic Oncology Group Elderly Working Group
2014- NRG/Gynecologic Oncology Group Committee of Ovarian Cancer
2014- NRG/Gynecologic Oncology Group Committee of Phase I Clinical Trials
2014- NRG/Gynecologic Oncology Group Developmental Therapeutics Committee (DT Cervix Cancer co-Chair 2016-2018)

International

2020-2022 Committee leader for the 5th Ovarian Cancer Consensus Conference meeting

Committee Assignments:

Local

2019- American Society of Clinical Oncology(ASCO) Somatic Genomic Panel Testing in Metastatic Disease Guideline Panel
2019- ASCO PARPi Use in Ovarian Cancer Guideline Panel
2019-2021 ASCO Annual Meeting Education Committee Member
2019-2021 ASCO pre Annual Meeting Seminar, New Drugs in Oncology Planning Committee
2018-2021 Foundation for Women's Cancers Scientific Awards Committee
2018-2021 NCI Clinical Trials Planning Committee (CTPM) (ovary)
2015-2018 ASCO Clinical Practice Committee
2015-2020 Society of Gynecologic Oncology Nominating Committee
2015-2016 Society of Gynecologic Oncology Annual Meeting Steering Committee
2014- Oral Examiner, American Board of Obstetrics and Gynecology, American Board of Obstetrics and Gynecology
2014-2018 Society of Gynecologic Oncology Clinical Practice Committee
2013-2014 Society of Gynecologic Oncology Annual Meeting Steering Committee
2012-201 Gynecologic Cancer Steering Committee
2011-2012 Society of Gynecologic Oncology Annual Meeting Program Committee

International

2020-2022 GCIG Ovarian Cancer Consensus Conference Delegate
2014-2015 GCIG Ovarian Cancer Consensus Conference Delegate

Grant Review Activities

2020- OvaCure Innovation Challenge Scientific Board (Copenhagen)
2020- Washington University Endometrial Spore EAB
2020- Mayo Clinic Ovarian Spore EAB

Invited Presentations

Local/Institutional (past five years):

2021 Changing paradigms for the treatment of ovarian cancer", 9th Annual Scientific Symposium, Basser Center for BRCA
April 2021 23rd Annual Goodrich Clark Lecture- Johns Hopkins

March 2021	Grand Rounds Mayo: Front line ovarian cancer
December 2020	Ovarian Cancer Grand Rounds for Hematology Oncology at the University of Oklahoma
April 2019	Visiting professorship at University of Alabama: Immunotherapy in Gynecologic Cancers
aand	
	Changing Paradigms in Front Line Ovarian Cancer
December 2019	MD Anderson Gynecologic Surgery Grand Rounds: How to Develop a Clinical Trials Unit
December 2018	Grand Rounds SUNY Downstate: PARP inhibitors and checkpoint inhibitors in gynecologic cancer: Novel therapies to improve patient outcomes
December 2018	Grand Rounds University of Minnesota: Phase I Clinical Trials: What they are and what you need to know to start a unit
December 2018	St John Cancer Center Symposium: Immuno-oncology: Transforming Cancer Care
2017	Grand rounds: Treatment of uterine Leiomyosarcoma, University of Hawaii Cancer Center
April 2017	Probstein Gyn Onc Lecturer, OB/GYN Grand Rounds, Washington University

National (past five years)

August 2021	Emerging Immunotherapies & Novel Therapeutics", Emerging Immunotherapies & Novel Therapeutics in Endometrial Symposium, Gynecologic Oncology Group(GOG) Foundation
August 2021	A Value Based Framework in the Clinical Integration of PARP Inhibitors in the Management of Ovarian Cancer", Medscape CME Program, Medscape
August 2021	Oklahoma GeroOncology Symposium-A Deeper Dive into the Inner Workings of Aging in Cancer, Stephenson Cancer Center and Oklahoma Nathan Shock Aging Center
August 2021	Emerging Immunotherapies & Novel Therapeutics in Endometrial Symposium, Gynecologic Oncology Group (GOG) Foundation
June 2021	Western Association of Gynecologic Oncology (WAGO) Annual Meeting ASCO update
April 2021 and October 2021	Great Debates and Updates Gynecologic Cancer Course – Course director
June 2020	Western Association of Gynecologic Oncology (WAGO) Annual Meeting ASCO update
April 2020	Association of Managed Care Pharmacists (Virtual) Panel Discussion of PARPi use, cost effectiveness and formulary decisions
March 2020	Society of Gynecologic Oncology Annual Meeting: Virtual: Distillat for the Rise of PARPi
February 2020	Miami General Medical Oncology Symposium
February 2020	Society of Gynecologic Oncology Winter Meeting: Paradigm Changes in Front line Ovarian Cancers
April 2019	Oncology Nurses Society Annual Meeting
April 2019	New Therapies in Ovarian Cancer, PARPi
March 2019	Society of Gynecologic Oncology Annual Meeting 2019, Resident, Fellow and Candidate Session: Ovarian Cancer Clinical Trials
March 2019	Society of Gynecologic Oncology Annual Meeting 2019, SGO Education Session: Immunotherapy in Gynecologic Cancers
March 2019	American College of Medical Genetics Annual Meeting, Genetic Testing in Ovarian Cancer
2019	Western Association of Gynecologic Oncology ASCO Update
2019	ASCO Annual Meeting Session Chair: From Pharma to Table; Biomarkers of Immunotherapy in Gynecologic Cancers
2019	ASCO New Drugs Seminar: FDA Approvals and their incorporation in to clinical practice: Olaparib and Talazoparib in Breast and Ovarian Cancer
2018	Western Association of Gynecologic Oncology ASCO Update
2017	SGO Winter Meeting, PARPi Use in Ovarian Cancer: A Pro Con Debate
2017	SGO Annual Meeting, Antibody Drug Conjugates in Ovarian Cancer
2017	American Society of Clinical Oncologists Annual Meeting, Investigational New Drugs in Oncology Session Rucaparib
2017	American Society of Clinical Oncologists Annual Meeting, Perioperative Considerations in the Older Endometrial Cancer Patient
2017	Western Association of Gynecologic Oncology ASCO Update
2017	Western Association of Gynecologic Oncology, Molecular Tumor Board for Gynecologic Cancers

International (past five years)

June 2021	Changes and challenges in the treatment paradigm for front line ovarian cancer, Ovarian Cancer Symposium, Ovarian Cancer Australia
May 2021	Advances in Frontline Treatment Options for Patients With Ovarian Cancer, 12th Annual

	International Symposium on Ovarian Cancer and Other Gynecologic Malignancies, Immuno-Oncology Group
2021	"Ovarian carcinoma: systemic therapies", Next Frontiers to Cure Cancer 2021 Congress
September 2020	Front Line Ovarian Cancer: Paradigm Changes", Academic Grand Rounds for Central and South American Gyn Oncs, Global Cancer Institute
September 2020	4 th Egyptian Gynecologic Oncology Conference: Controversies in Management of Front Line Ovarian Cancer
September 2020	The 4 th Egyptian GO, Egyptian Gynecological Oncology
September 2020	G-CIGO invited grand rounds (Central and South American Gynecologic Oncology Tumor board) Front line ovarian cancer: Paradigm Changes grand rounds
June 2020	Gynecologic Oncology Intergroup (GFIG) biannual meeting NCI report
May 2020	11 th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies, Front line management of ovarian cancer
May 2020	Ovarian Cancer Maintenance Therapy (Including PARP and Possible Role of Immunotherapy)", 20 th Continuing Professional Development Meeting, The Society of Gynecologic Oncology of Canada
November 2019	Gynecologic Oncology Symposium, Platinum Resistant Ovarian Cancer: Treatment Strategies
July 2019	Developmental Therapeutics in Ovarian Cancer, Congress on Women's Health Innovations & Inventions
2019	International Gynecologic Cancer Society Annual Meeting, Changing Paradigms in Ovarian Cancer Therapy
September 2018	Systemic Therapy for Metastatic Endometrial Cancer - Present and Future", International Gyn Cancer Society Meeting
2018	International Gynecologic Cancer Society (IGCS), Immune oncology in endometrial cancer
2018	European Society of Medical Oncology, PARP Inhibition in Ovarian Cancer: Is it time for a paradigm shift?

Presentations to Patients/Families (past five years)

April 2019	"Cancer 101", NACCDO-PAMN
September 2018	Gynecologic Cancer Foundation Survivor Course, Clinical Trials In Gynecologic Cancers
2016-	Stephenson Cancer Center Survivor Course Director (on hold 2020-2021)

D. EDUCATION AND MENTORSHIP

Faculty Mentorship/Sponsorship:

Rachel Grisham, MD (MSKCC): I served as the mentor for Dr. Grisham on the CTEP project team for peposertib (DNA PK inhibitor) which lead to the now accruing ETCTN 10324. Dr. Grisham and I have continued to work together on clinical trials, especially those for low grade ovarian cancer as Dr. Grisham has established herself as an international expert in the treatment of these challenging tumors.

Camille Gunderson, MD (formerly Stephenson Cancer Center): I served as Dr. Gunderson's mentor during fellowship and her 6 years at Stephenson Cancer Center. I worked with her to develop the multi-site phase 2 study of atezolizumab and bevacizumab in recurrent endometrial cancer and we submitted this successfully for her to attend the ASCO/AACR clinical trials workshop. I also provided mentorship on how to write and oversee multi-site IITs for her trial evaluating galunisertib and paclitaxel and carboplatin in uterine carcinosarcomas. Both of these trials have recently completed and have been submitted to the International Gynecologic Cancer Society 2022. I also served as a mentor for Dr. Gunderson on her successful application to the CTEP project team for abemaciclib which resulted in the now activated ETCTN 10422.

Katherine Fuh, MD PhD (Siteman Cancer Center): I serve as a mentor/sponsor for Dr. Fuh through our participation on the CTEP project team for ipatasertib which has led to her about to activate study NRG GY027 – a phase 1 study of paclitaxel, carboplatin and ipatasertib in the treatment of front line ovarian cancer. I also serve as her mentor for the NRG Scholars award which is a 5 year funded award aimed at developing promising clinical trialists into drug developers. I serve as her formal mentor as she leads the international phase 3 trial of weekly paclitaxel +/- AVB500 in platinum resistant ovarian cancer (GOG 3059). We are currently working together to develop a trial of AVB500 plus PARP inhibitor based on her published preclinical work and have promoted Dr. Maggie Mullen (junior faculty at Siteman) to attend the ASCO/AACR Vail workshop with this concept.

Debra Richardson, MD (Stephenson Cancer Center): I serve as Dr. Richardson's NRG Scholars mentor and have been mentor/sponsoring her as she serves as the US PI for the single arm phase 2 of upifitamab in platinum resistant ovarian cancer which is being run with registration intent. Dr. Richardson is the international PI for the close to activating UPNEXT study which integrates upifitamab into the platinum sensitive maintenance space. We work closely on investigator initiated trials and I serve as her mentor on the STAR trial which is a multi-site IIT evaluating dostarlimab and niraparib in recurrent cervical cancer.

Christina Washington, MD (Stephenson Cancer Center): I serve as a mentor to Dr. Washington as she has entered her first year as an attending after completing her fellowship at Stephenson. I am her thesis chair (described above) and her mentor for the invited invitation for the BMSF diversity in clinical trials 2 year program. I provide mentorship to Dr. Washington as she took over leading 2 already active IITs at our site and am providing mentorship and eventual sponsorship for a new multi-site IIT evaluating VS 6766 (MEK/RAF) inhibitor plus defactinib in KRAS altered gynecologic cancers (not low grade serous). Dr. Washington will lead this as the US PI. Dr. Washington was selected for participation in the 2022 ASCO/AACR Clinical trials workshop where I will serve as her mentor.

Tara Castellano, MD (LSU): I serve as a formal mentor for Dr. Castellano as she is a selected BMSF diversity in clinical research awardee. I participated in community research training/orientation provided by the program and am currently working with Dr. Castellano to open the first of several planned clinical trials in the LSU "Steel Magnolias" network which brings trials to remote communities in Louisiana. I have been able to use my position as AD for GOG Partners and Director of the investigator council to nominate Dr. Castellano for the committee on diversity and inclusion in clinical trials and she has already worked with this committee on an forthcoming evaluation of geographic distribution of cervical cancer in the US (ASCO 2022).

Christina Henson, MD (Stephenson Cancer Center): I serve as a mentor for Dr. Henson who is a radiation oncologist at the Stephenson. She has already developed an IIT which is up and accruing in head and neck cancer for which I serve as a mentor. Most recently she developed a protocol evaluating the DNA PK inhibitor peposertib in recurrent cervical cancer with focal SBRT to up to 3 metastases. This project had collaboration from Dr. Rachel Grisham (see above) and her team at MSKCC to develop the needed pre-clinical data (PMID: 35046420) and collaboration with the industry sponsor regarding design. This was approved all the way through research strategy at NRG and then was disapproved by IDB. Dr. Henson's work and expertise was recognized by the NRG cervix leadership however and she has been named the CRDL investigator for another trial proposal with Jyoti Mayadev, MD as a mentor. I will remain an unofficial mentor on this project on the local level.

Rebecca Arend MD, PhD (UAB) who is a CRDL eligible investigator who I am currently mentoring on a multi-arm phase I trial in front line ovarian cancer as well as a randomized phase 2 trial in front line ovarian cancer incorporating the nuclear exportin inhibitor selinexor. Both of these trials were developed as a part of the CTEP sponsored clinical trials planning meeting for ovarian cancer.

Haider Madhi MD (UPMC): I have served as a mentor for Dr. Madhi for multiple concepts he has brought forth to the NRG based on preclinical work generated in his lab. We worked most closely on NRG GY025 which is evaluating nivolumab and ipilimumab vs. nivolumab in recurrent endometrial cancer and allows prior ICI exposure which is one of the first trials to do so. As AD for GOG Partners, I have worked to position Dr. Madhi on scientific advisory boards for assets in his research pipeline (such as CD47 inhibitors) where he can demonstrate his expertise and further develop his career.

BJ Rimel MD (Cedars Sinai, LA): Dr. Rimel is a longtime mentee of mine and I am very proud of what she has accomplished. She was just named the medical director for the CTO in recognition of her clinical trial excellence and we are currently working together on a randomized phase 2 trial in front line, local regional cervical cancer as well as a second trial of a CDK4/6 inhibitor in low grade serous ovarian cancer. Dr. Rimel is an example of mentorship to sponsorship where- at this point – I just position her in a place of opportunity and she takes over with high quality deliverables.

E. BIBLIOGRAPHY

Limited to first/senior author and/or high impact

Peer Reviewed Research Investigations:

Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, **Moore KN**. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. *J Clin Oncol*. 2022 Apr 19;JCO2101801. doi: 10.1200/JCO.21.01801. Epub ahead of print. PMID: 35439029.

Chakravarty D, Johnson A, Sklar J, Lindeman NI, **Moore K**, Ganesan S, Lovly CM, Perlmutter J, Gray SW, Hwang J, Lieu C, André F, Azad N, Borad M, Tafe L, Messersmith H, Robson M, Meric-Bernstam F. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. *J Clin Oncol*. 2022 Apr 10;40(11):1231-1258. doi: 10.1200/JCO.21.02767. Epub 2022 Feb 17. PMID: 35175857.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, **Moore KN**, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. *Lancet*. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9. PMID: 35123694; PMCID: PMC8819271.

Powell MA, Filiaci VL, Hensley ML, Huang HQ, **Moore KN**, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. *J Clin Oncol*. 2022 Mar 20;40(9):968-977. doi: 10.1200/JCO.21.02050. Epub 2022 Jan 10. PMID: 35007153; PMCID: PMC8937015.

Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, **Moore KN**, Stagg R, Kapoun AM, Faoro L, Sharma S. A Phase 1a/b Open-Label, Dose-Escalation Study of Etipilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. *Clin Cancer Res*. 2022 Mar 1;28(5):882-892. doi: 10.1158/1078-0432.CCR-21-2780. PMID: 34844977.

Banerjee S, **Moore KN**, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26. Erratum in: *Lancet Oncol*. 2021 Dec;22(12):e539. PMID: 34715071.

Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ, Troso-Sandoval TA, Cragun JM, Rodrigo Imedio E, Kumar S, Mugundu GM, Lai Z, Chmielecki J, Jones SF, Spigel DR, Cadoo KA. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. *Clin Cancer Res*. 2022 Jan 1;28(1):36-44. doi: 10.1158/1078-0432.CCR-21-0158. Epub 2021 Oct 13. PMID: 34645648.

Liu J, Burris H, Wang JS, Barroilhet L, Gutierrez M, Wang Y, Vaze A, Commerford R, Royer-Joo S, Choerung V, Humke E, **Moore K**. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. *Gynecol Oncol*. 2021 Dec;163(3):473-480. doi: 10.1016/j.ygyno.2021.09.023. Epub 2021 Oct 6. PMID: 34627611.

Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, **Moore K**, DiSilvestro P. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. *Eur J Cancer*. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28. PMID: 34597975.

Moore KN, Hong DS, Patel MR, Pant S, Ulahannan SV, Jones S, Meric-Bernstam F, Wang JS, Aljumaily R, Hamilton EP, Wittchen ES, Wang X, Lin AB, Bendell JC. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. *Target Oncol*. 2021 Sep;16(5):569-589. doi: 10.1007/s11523-021-00835-0. Epub 2021 Sep 24. PMID: 34559360.

Fuh KC*, Bookman MA, Liu JF, Coleman RL, Herzog TJ, Thaker PH, Monk BJ, Anderson R, McIntyre G, Rangwala R, **Moore KN**. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. *Gynecol Oncol*. 2021 Nov;163(2):254-261. doi: 10.1016/j.ygyno.2021.08.020. Epub 2021 Aug 30. PMID: 34474927.

Morice PM, Ray-Coquard I, **Moore KN**, Diéras V, Alexandre J. PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials. *Ann Oncol*. 2021 Aug;32(8):1048-1050. doi: 10.1016/j.annonc.2021.04.023. Epub 2021 Jun 6. PMID: 34107345.

Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Lontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). *J Clin Oncol*. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23. Erratum in: *J Clin Oncol*. 2021 Jul 20;39(21):2420. PMID: 33891472; PMCID: PMC8189598.

Friedlander M, **Moore KN**, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. *Lancet Oncol*. 2021 May;22(5):632-642. doi: 10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13. PMID: 33862001.

Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. *Ann Oncol*. 2021 Jun;32(6):757-765. doi: 10.1016/j.annonc.2021.02.017. Epub 2021 Mar 2. PMID: 33667670.

Hong DS, **Moore KN**, Bendell JC, Karp DD, Wang JS, Ulahannan SV, Jones S, Wu W, Donoho GP, Ding Y, Capen A, Wang X, Bence Lin A, Patel MR. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. *Clin Cancer Res*. 2021 Apr 1;27(7):1864-1874. doi: 10.1158/1078-0432.CCR-20-3242. Epub 2021 Jan 25. PMID: 33495309.

Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, **Moore K**, O'Reilly EM, Ray-Coquard I, Alexandre J. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. *Lancet Haematol*. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18. Erratum in: *Lancet Haematol*. 2021 Feb;8(2):e105. PMID: 33347814.